Costs to prevent sickle cell disease out of reach for many in India: Lancet Commission

According to the Lancet Commission, the costs associated with preventing
sickle cell disease in India are beyond the reach of most individuals.
Sickle cell disease is a genetic disorder that affects hemoglobin, causing
red blood cells to become rigid and sickle-shaped. The commission
highlights that the cost of comprehensive care and treatment, including
screening, preventive measures, and access to affordable medication, is
prohibitively high for many affected individuals. This puts a significant
burden on patients and their families, exacerbating health inequities. The
Lancet Commission calls for increased investment in healthcare
infrastructure and policies that prioritize affordability and accessibility
to tackle the challenges associated with sickle cell disease in India.